Global Drug Overdose Pipeline Guide, H1 2020: Therapeutics Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type

DUBLIN, April 22, 2020 /PRNewswire/ -- The "Drug Overdose - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 1, 3, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Drug Overdose (Toxicology).
    --  The pipeline guide reviews pipeline therapeutics for Drug Overdose
        (Toxicology) by companies and universities/research institutes based on
        information derived from company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
        stages.
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Drug Overdose
        (Toxicology) therapeutics and enlists all their major and minor
        projects.
    --  The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics
        based on mechanism of action (MoA), drug target, route of administration
        (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Drug Overdose (Toxicology).

Reasons to Buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Drug Overdose (Toxicology).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
        companies.
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Drug Overdose (Toxicology) pipeline depth and focus of Indication
        therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Companies Mentioned

    --  Adamis Pharmaceuticals Corp
    --  Amphastar Pharmaceuticals Inc
    --  Crossject SA
    --  Emergent BioSolutions Inc
    --  Fab'entech SA
    --  Icure Pharmaceutical Inc
    --  Insys Therapeutics Inc
    --  iQure Pharma Inc
    --  Klaria Pharma Holding AB
    --  Mucodel Pharma LLC
    --  Opiant Pharmaceuticals Inc
    --  Orexo AB
    --  PledPharma AB
    --  ResQ Pharma Inc
    --  Vallon Pharmaceuticals Inc
    --  Worphmed Srl

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dv1as3

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-drug-overdose-pipeline-guide-h1-2020-therapeutics-analysis-by-stage-of-development-drug-target-mechanism-of-action-route-of-administration-and-molecule-type-301045452.html

SOURCE Research and Markets